Comparative Post‐Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
- 19 November 2024
- journal article
- research article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (11) , e70018
Abstract
Objectives: The aim of this study was to conduct a comparative analysis of the proportion of cardiovascular adverse events (AEs) associated with the utilization of memantine and cholinesterase inhibitors and to highlight the potential impact of sex differences in these AEs.Methods: Cardiac and vascular disorders AEs with antidementia medications were obtained from the FDA Adverse Event Reporting System database. The reporting odds ratio and its corresponding 95% confidence intervals were calculated. The chi‐squared test was used to evaluate differences in categorical variables, and a two‐way ANOVA followed by a Bonferroni post‐test was used to compare the AEs reported for antidementia medications.Results: Memantine was associated with 544 selected cardiac and vascular disorder AEs. A signal for bradycardia, myocardial infarction, atrial fibrillation and cardiac arrest has been observed in patients receiving choline esterase inhibitors compared to those receiving memantine. On the other hand, cardiac failure and deep vein thrombosis AEs were found to be more common in patients receiving memantine. The majority of reported cardiac and vascular AEs were reported more frequently in female patients. More cases of cardiac failure, cardiac arrest, and deep vein thrombosis were reported in females than males taking memantine, but bradycardia was more common in males than females.Conclusion: Healthcare professionals should be aware of the potential for cardiovascular AEs during treatment with antidementia medications and the possibility of sex differences in this regard. Memantine differs from cholinesterase inhibitors in terms of cardiovascular AEs, and there may be sex‐related differences in the proportion of these AEs.Keywords
This publication has 54 references indexed in Scilit:
- Gender and CVD- Does It Really Matters?Current Problems in Cardiology, 2023
- Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a centuryeClinicalMedicine, 2019
- Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer DiseaseJAMA Network Open, 2019
- Memantine, an NMDA receptor antagonist, attenuates cardiac remodeling, lipid peroxidation and neutrophil recruitment in heart failure: A cardioprotective agent?Biomedicine & Pharmacotherapy, 2018
- Sex matters to the heart: A special issue dedicated to the impact of sex related differences of cardiovascular diseasesAtherosclerosis, 2015
- The Effects of Sex on Out-of-Hospital Cardiac Arrest OutcomesThe American Journal of Medicine, 2011
- A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitorsInternational Journal of Geriatric Psychiatry, 2010
- Does memantine induce bradycardia? A study in the French PharmacoVigilance DatabasePharmacoepidemiology and Drug Safety, 2008
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- On the role of NMDA receptors in blood pressure regulation in spontaneously hypertensive rats (SHR)Amino Acids, 1995